![]() |
Move over FIDO, let's all open wide...detection of breast cancer markers in saliva
J Oral Pathol Med. 2006 May;35(5):292-300. Related Articles, Links
The use of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to detect putative breast cancer markers in saliva: a feasibility study. Streckfus CF, Bigler LR, Zwick M. Professor, Diagnostic Sciences, University of Texas at Houston Health Science Center Dental Branch, Houston, TX, USA. Background: Technologies are now available enabling saliva to be used to diagnose disease, predict disease progression, and monitor therapeutic efficacy. This pilot study describes the use of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI) to detect putative breast cancer markers in saliva. Methods: Salivary specimens were analyzed as either pooled cancer saliva specimens, or individual specimens from healthy women and women diagnosed with carcinoma of the breast. The specimens were applied to a variety of protein chip arrays, washed extensively to remove unbound analytes and analyzed on a SELDI mass spectrometer. Results: The results of this initial study suggest that the WCX protein chip array prepared and washed at pH 3.5 yielded the most promising results. Additionally, the analyses revealed a number of proteins that were higher in intensity among the cancer subjects when compared with controls. These salivary proteins were present at the 18, 113, 170, 228 and 287 km/z ranges using SELDI analyses. Conclusions: The study suggests that saliva may be useful for high-throughput biomarker discovery. PMID: 16630293 [PubMed - in process] |
Lani
If this is an open article and if the protein markers are listed do you have a link or list of markers. I tried a google and NCBI search but did not find it, and have less time than usual. Very many thanks RB |
found lots of recent articles I could not access
this 2001 I could and excerpt here:
Reliability analysis The reliability analyses are shown in Table IV. With the exception of salivary total protein, the results suggest a decrease in intracorrelations with respect to time across the 5 days of sampling. The 9 AMsampling time produced the best intercorrelation and intracorre- lation coefficients for sampling time across all 4 param- eters (Table IV). DISCUSSION It is difficult to compare the results of these findings with those in the literature. Very few investigators have studied the technical issues associated with the c-erbB- 2 marker.5A variety of analytical techniques have also been used to study the c-erbB-2 oncoprotein in both tissue and serum.2With respect to serum, most studies have used enzyme-based immunoassays.2,5These tech- niques have varied with respect to the sensitivity of the assays and the use of either monoclonal or polyclonal antibodies.13Some kits used in the literature have since been discontinued and are no longer available to researchers. A question that might be raised is,how does a 185 kd protein enter the saliva? There is a lot that we do not comprehend about salivary function and, in particular, protein secretion. We do know that large proteins,such as cytokines,and growth factors are found in saliva and often reflect changes of magnitude according to the individual’s health.14 Using commercially available antibodies directed against the extracellular domain of the c-erbB-2 protein, we have determined by western blot analysis that the protein detected in saliva is, indeed,c-erbB-2. The presence of c-erbB-2 in saliva is either by active transport or leakage. It is quite possible that extracellular stimuli may initiate expression of proto-ocogenes in epithelial tissues.15Further research is required to determine which mechanism is respon- sible for the presence of the c-erbB-2 protein in saliva. In comparing the values with those presented in a previous study,8 we found that the mean values for healthy women in the earlier study were 71.30 units/ mg protein, whereas the individuals with carcinoma of the breast were 143.58 units/mg protein. There were no significant differences between men and women with respect to salivary c-erbB-2 concentra- tions. This is the first report of the presence of c-erbB- 2 in the saliva of men and may have future diagnostic potential for the detection of malignant disease among this cohort of individuals. Th Collectively, these additional analyses suggest that it would be more reliable for the dentist to perform the saliva collection. Additionally, it may even be more prudent to perform the salivary collections during the morning hours. In summary, the results of this study suggest that c- erbB-2 can be detected in healthy men and is compa- rable in value with healthy women. This may initiate opportunities for the use of salivary c-erbB-2 as a diag- nostic media for the detection of carcinomas among men. In addition, morning and early evening collec- tions do not affect salivary c-erbB-2 concentrations. Finally, c-erbB-2 appears to be a very reliable salivary marker, especially when the collections are supervised by a dentist or trained health care practitioner and are performed during the morning hours. |
Thanks for your trouble.
Interesting. On my "fats" trail I found a trial on skeletal muscular tissue in mice. Higher ratios of omega three v omega six reduced expression of erbB-2 C-neu by fifty percent. Interestingly this trial is showing a 100% lift to. Significant I have no idea. Intrigueing - definately. Other genes and proteins were also cited. As usual I wish they would do some large scale tests in humans based on tissue biopsies of breast waist and gluteal fats looking at the BC related markers concurrently both short term and long term. I was hoping maybe they had looked at other genes proteins too as part of the tests to add to my information. I am busy doing other things at the moment but hope to get back to my wanders at some point. Thanks again for your continuing efforts. RB |
| All times are GMT -7. The time now is 08:30 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021